We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Urethra-sparing high-intensity focused ultrasound for localized prostate cancer: Functional and oncological outcomes.
- Authors
Shoji, Sunao; Nakano, Mayura; Fujikawa, Hiroshi; Endo, Kazuyuki; Hashimoto, Akio; Tomonaga, Tetsuro; Terachi, Toshiro; Uchida, Toyoaki
- Abstract
Objectives To evaluate longitudinal changes in urinary function and quality of life, and the oncological outcomes of patients treated with urethra-sparing high-intensity focused ultrasound for localized prostate cancer. Methods Patients with negative findings in the urethra and the anterior urethral zone using transrectal ultrasound-guided targeted biopsies, and magnetic resonance imaging, received urethra-sparing or whole-gland high-intensity focused ultrasound as the primary therapy for localized prostate cancer without transurethral resection of the prostate. Longitudinal changes in urinary function and quality of life, and the oncological outcomes of the patients were analyzed retrospectively. Results The median follow-up times for urethra-sparing and whole-gland high-intensity focused ultrasound were 36 and 30 months, respectively. Comparing the patients treated with urethra-sparing high-intensity focused ultrasound ( n = 45) with those treated with whole-gland high-intensity focused ultrasound ( n = 65), there were significant differences in the International Prostate Symptom Score ( P = 0.014) at 3 months, International Prostate Symptom Score quality of life ( P = 0.033) at 3 months, maximum urinary flow rate (mL/s; at 3 months, P = 0.010; at 6 months, P = 0.038) and residual urine volume (mL; at 3 months, P < 0.0001; at 6 months, P = 0.016; at 12 months, P = 0.028). For quality of life, there were significant differences in Functional Assessment of Cancer Therapy - General (at 3 months, P = 0.022) and Functional Assessment of Cancer Therapy - Prostate (at 3 months, P = 0.028; at 6 months, P = 0.034). There were no significant differences in oncological outcomes regarding negative biopsy rates on follow up (91% vs 92%; P = 0.8) or biochemical disease-free survival rates (86.7% vs 89.2%; P = 0.7). Conclusions Urethra-sparing high-intensity focused ultrasound might prevent prolonged bladder outlet obstruction, and could be a treatment option for localized prostate cancer.
- Subjects
PROSTATE cancer treatment; TRANSURETHRAL prostatectomy; DIAGNOSTIC ultrasonic imaging; BLADDER diseases; URETHRA physiology; HEALTH outcome assessment; MAGNETIC resonance imaging; PREVENTION
- Publication
International Journal of Urology, 2015, Vol 22, Issue 11, p1043
- ISSN
0919-8172
- Publication type
Article
- DOI
10.1111/iju.12876